1258 Upsala Rd
Sanford, FL 32771
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2023 All rights reserved
AGAOBE01233a
Disclaimer
is resource is for informational purposes only, intended as a quick-reference tool based on the cited
source guideline(s), and should not be used as a substitute for the independent professional judgment
of healthcare providers. Practice guidelines are unable to account for every individual variation
among patients or take the place of clinician judgment, and the ultimate decision concerning the
propriety of any course of conduct must be made by healthcare providers aer consideration of each
individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline
recommendations and has not independently verified the accuracy hereof. Any use of this resource or any
other Guideline Central resources is strictly voluntary.
Abbreviations
AGA, American Gastroenterological Association; AOM, anti-obesity medications; bid, twice
a day; BMI, body mass index; ER, extended release; FDA, Food and Drug Administration;
GI, gastrointestinal; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MEN 2, Multiple
Endocrine Neoplasia syndrome type 2; MAOI, monoamine oxidase inhibitor; MTC,
medullary thyroid carcinoma; max, maximum; mg, milligrams; PO, by mouth; q, every;
subcut, subcutaneous; T2DM, type 2 diabetes mellitus; tid, three times a day
Source
Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological
Interventions for Adults With Obesity. Gastroenterolog y. 2022;163:1198–1225.
doi: 10.1053/j.gastro.2022.08.045.
Visit gastro.org/guidelinesapp to learn about the AGA Clinical Guidelines App.
Available for download on the iTunes and Google Play Store.
AGA Clinical Practice Guideline on Pharmacological Interventions
for Adults With Obesity
